Association Between Tadalafil and Macular Edema
There is a documented association between tadalafil and macular edema, though the evidence suggests this is a rare adverse event. The FDA drug label for tadalafil specifically lists retinal vein occlusion as a postmarketing adverse event, and retinal vein occlusion is a well-established cause of macular edema 1.
Evidence from FDA Drug Labeling
The FDA-approved tadalafil label explicitly identifies retinal vein occlusion in the postmarketing experience section 1. Since retinal vein occlusion causes macular edema in approximately 30% of cases, this creates a direct mechanistic link between tadalafil use and potential macular edema development 2.
The drug label also reports:
- Visual field defects and retinal artery occlusion as rare postmarketing events 1
- Changes in color vision occurring in less than 0.1% of patients across clinical trials 1
- Blurred vision and conjunctival hyperemia as less frequent adverse events 1
Supporting Research Evidence
Recent pharmacovigilance data strengthens this association:
A 2025 nationwide study identified sildenafil (another PDE5 inhibitor in the same drug class as tadalafil) among the top signals for maculopathy, with an incidence rate ratio of 2.75 (95% CI, 2.17-3.48) comparing exposure versus pre-exposure periods 3. This suggests a class effect for PDE5 inhibitors.
A 2024 prospective study of tadalafil 20 mg used on alternate days demonstrated measurable retinal vascular changes after 6 months, including statistically significant reductions in deep capillary plexus and choriocapillaris vessel density 4. While this study did not report frank macular edema, the documented vascular alterations indicate tadalafil affects retinal microcirculation.
A 2012 case report documented reversible photoreceptor damage with pseudo-serous retinal detachment appearance on OCT following tadalafil use, which resolved after drug discontinuation 5. This demonstrates that tadalafil can cause structural macular changes.
Clinical Context and Mechanism
The mechanism likely involves:
- PDE5 inhibition affecting retinal vascular regulation 4
- Potential precipitation of retinal vein occlusion in susceptible individuals 1
- Direct effects on retinal microvascular permeability 4
Importantly, a 2009 randomized controlled trial of daily tadalafil 5 mg or sildenafil 50 mg for 6 months found no significant changes in electroretinography, visual function, or intraocular pressure 6. This suggests that at standard therapeutic doses, retinal toxicity is uncommon, but the postmarketing surveillance data indicates it does occur in real-world use.
Clinical Recommendations
Monitor patients taking tadalafil for visual symptoms including:
- Sudden vision changes or vision loss 1
- Visual field defects 1
- Color vision disturbances 1
- Blurred vision 1
Discontinue tadalafil immediately if patients develop:
- Sudden decrease or loss of vision 1
- Symptoms suggestive of retinal vein occlusion (sudden painless vision loss, visual field defect) 1
- Persistent visual disturbances 5
Exercise particular caution in patients with:
- Pre-existing retinal vascular disease 1
- Diabetes, hypertension, hyperlipidemia (risk factors for retinal vein occlusion) 2
- Age over 50 years 1
- History of cardiovascular disease 1
Important Caveats
The absolute risk remains low—visual adverse events are classified as rare (less than 0.1%) in clinical trials 1. However, postmarketing surveillance suggests the real-world incidence may be higher than captured in controlled trials 3. The temporal association reported in postmarketing cases makes it impossible to definitively establish causation versus correlation with underlying vascular risk factors 1.